BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. In late 2019, it became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed Cell & Gene Therapy Platform.

The company's cell & gene therapy platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.